Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.